Cantor Fitzgerald Analysts Lower Earnings Estimates for TSHA

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) – Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of Taysha Gene Therapies in a report released on Wednesday, November 5th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings of ($0.37) per share for the year, down from their previous estimate of ($0.34). The consensus estimate for Taysha Gene Therapies’ current full-year earnings is ($0.35) per share. Cantor Fitzgerald also issued estimates for Taysha Gene Therapies’ FY2026 earnings at ($0.48) EPS.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. The company had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.51 million.

Several other brokerages also recently commented on TSHA. Bank of America initiated coverage on shares of Taysha Gene Therapies in a report on Friday, July 11th. They set a “buy” rating and a $8.00 price target on the stock. Citigroup restated an “outperform” rating on shares of Taysha Gene Therapies in a research report on Wednesday. JMP Securities set a $8.00 target price on Taysha Gene Therapies in a research note on Wednesday. Citizens Jmp raised their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “market outperform” rating in a research note on Wednesday. Finally, Needham & Company LLC restated a “buy” rating and set a $10.00 price objective on shares of Taysha Gene Therapies in a report on Friday, October 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.70.

Taysha Gene Therapies Trading Down 2.7%

Shares of TSHA opened at $3.92 on Friday. The company’s fifty day simple moving average is $3.97 and its 200-day simple moving average is $3.05. The company has a market cap of $1.07 billion, a P/E ratio of -11.88 and a beta of 1.00. The company has a current ratio of 10.48, a quick ratio of 12.48 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies has a twelve month low of $1.05 and a twelve month high of $5.51.

Insider Buying and Selling at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $3.23, for a total value of $646,000.00. Following the completion of the sale, the insider owned 1,006,439 shares in the company, valued at approximately $3,250,797.97. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 3.78% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Principal Financial Group Inc. lifted its holdings in shares of Taysha Gene Therapies by 33.6% in the 3rd quarter. Principal Financial Group Inc. now owns 16,251 shares of the company’s stock worth $53,000 after buying an additional 4,091 shares during the period. ST Germain D J Co. Inc. increased its stake in shares of Taysha Gene Therapies by 81.8% during the third quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after buying an additional 4,333 shares during the period. Granahan Investment Management LLC raised its holdings in shares of Taysha Gene Therapies by 0.3% in the first quarter. Granahan Investment Management LLC now owns 1,640,793 shares of the company’s stock valued at $2,281,000 after acquiring an additional 4,412 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in Taysha Gene Therapies by 51.9% in the second quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company’s stock worth $43,000 after acquiring an additional 6,350 shares during the period. Finally, Prudential Financial Inc. lifted its stake in Taysha Gene Therapies by 50.5% in the second quarter. Prudential Financial Inc. now owns 22,790 shares of the company’s stock worth $53,000 after acquiring an additional 7,650 shares during the period. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.